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A B S T R A C T
To assess inapparent visual field defects in patients with multiple sclerosis free from optic neuritis. During 5 years
period 120 patients with multiple sclerosis were examined at the University Department of Ophthalmology, Zagreb
University Hospital Center. They were divided into three groups with 40 patients each: patients with acute unilateral
optic neuritis, referred to ophthalmologist and treated with pulsed steroid therapy; patients with subjective feeling of
blurred vision, normal visual acuity and no signs of acute optic neuritis; and patients free from subjective signs of vi-
sual impairment. Study patients underwent standard ophthalmologic examination and visual field testing in pho-
topia by use of quantitative kinetic Goldmann perimetry. The initial and control examination by visual field testing
were performed at least 6 months apart. Study results showed 65% of multiple sclerosis patients to have visual field de-
fects without subjective signs of impaired vision. The most common defects were mild to moderate visual field narrow-
ing with blind spot enlargement and depression from above. The following results were recorded: acute optic neuritis
group: normal in 13/40 (32.5%) for the affected eyes and 27/40 (67.5%) for fellow eyes; mild visual field narrowing in
4/40 (10%) for the affected eyes and 10/40 (25%) for fellow eyes; moderate visual field narrowing with blind spot en-
largement in 14/40 (35%) for the affected eyes and 1/40 (2.5%) for fellow eyes; and paracentral and arcuate scotomata
in 9/40 (22.5%) for the affected eyes and 2/40 (5%) for fellow eyes; subjective symptom group: normal in 8/40 (20%) for
the affected eyes and 11/40 (27.5%) for fellow eyes; mild visual field narrowing in 11/40 (27.5%) for the affected eyes
and 16/40 (40%) for fellow eyes; moderate visual field narrowing with blind spot enlargement in 18/40 (45%) for the
affected eyes and 10/40 (25%); and paracentral and arcuate scotomata in 3/40 (7.5%) for both affected and fellow eyes;
and subjective symptom-free group: normal in 24/80 (30%), mild visual field narrowing in 22/80 (27.5%) moderate vi-
sual field narrowing with blind spot enlargement in 24/80 (30%); and paracentral and arcuate scotomata in 10/80
(12.5%). The presence of subclinical form of optic nerve involvement could be demonstrated in a very early stage of mul-
tiple sclerosis by the introduction of visual field testing in the standard examination protocol.
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Introduction
At present, there is a general consensus among re-
searchers and clinicians on a significant association be-
tween optic neuritis and multiple sclerosis (MS), as
many patients with a clinically definitive form of MS
have a history of acute optic neuritis during the course
of the underlying disease, and the clinically definitive
form of MS develops in many patients with a history of
optic neuritis1,2. Ebers believes that optic neuritis is a
forme fruste of MS3. Although optic neuritis is consid-
ered to be the most common ocular manifestation in MS
and could be the first sign of MS, visual system involve-
ment may also be asymptomatic or very discrete, with-
out any signs of visual acuity impairment or subjective
signs of visual field defects4,5. Using various functional
tests and visual evoked potentials, many authors dem-
onstrated involvement of the visual pathways in MS pa-
tients free from subjective signs of impaired vision6–9.
Study hypothesis was that visual field defects are also
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present in MS patients free from optic neuritis. There-
fore, in the present study perimetry was chosen as a
method to reveal vision function impairment. As these
defects involve eccentric, peripheral areas of the visual
field and progress at a slow rate, patients may fre-
quently fail to notice them. Thus, the aim of the study
was to investigate the prevalence, forms and extent of
visual field defects in MS patients in order to assess the
association between MS and most common visual field
defects. It was also intended to evaluate the role of
perimetry in the diagnosis of MS.
Patients and methods
Patients
This prospective study included 120 MS patients di-
agnosed according to Poser's criteria10. Neurologic defi-
cit and dysfunction were recorded as scores according to
the Expanded Disability Status Scale11. During 5 years
period from 1995 to 2000 patients were identified
through Neuroophthalmological division of University
Department of Ophthalmology, Zagreb University Hos-
pital Center and were divided into 3 groups of 40 pa-
tients each: 1) acute optic neuritis group; 2) subjective
symptom group; 3) subjective symptom-free group (Ta-
ble 1). Patient selection was based on the following cri-
teria: group 1 – acute optic neuritis group: unilateral
acute optic neuritis, normal visual acuity on the fellow
eye; normal visual acuity on the affected eye on control
examination at 6 months of therapy introduction; and
age 18–45 years. Only patients with unilateral optic
neuritis and normal visual acuity on control examina-
tion were included.; group 2 – subjective symptom
group: subjective symptoms occurring on one eye with
normal visual acuity bilaterally; no pulsed therapy for
at least 6 months preceding the onset of subjective
symptoms, between initial and control examination,
and at the time of control examination; and absence of
subjective symptoms on 6-month control examination
and age 18–45 years; and group 3 – subjective symp-
tom-free group: no history data on optic neuritis; ab-
sence of subjective signs of impaired vision; normal vi-
sual acuity bilaterally; and no pulsed therapy for at
least 6 months preceding the onset of subjective symp-
toms, between initial and control examination, and at
the time of control examination and age 18–45 years. No
case of optic neuritis recurrence was recorded during
the time between initial and control testing.
On planning the study, 3 groups of 45 subjects were
anticipated. During the study, three patients from the
subjective symptom group had to be excluded for wors-
ening of their neurologic symptoms and initiation of
pulse steroid therapy. Another two patients from the
same group failed to show up for control testing. Two pa-
tients from the subjective symptom-free group were ex-
cluded due to acute optic neuritis. In order to preserve
the balance design of the study, each group finally com-
prised of 40 patients. Patients with ocular lesions lead-
ing to visual function defects such as optic medium
opacity, retinal detachment, inflammatory lesions, de-
generative chorioretinal lesions, glaucoma, strabismus
and amblyopia were excluded. Patients with refraction
errors greater than 3 diopters were also excluded.
Methods
Patients were examined at University Department
of Ophthalmology, Zagreb University Hospital Center in
a standardised procedure. Standard ophthalmologic ex-
amination consisted of visual acuity measurement with
a Snellen chart, biomicroscopy, ophthalmoscopy, and
applanation tonometry. Pupillary reactions and bulbar
motoricity were also examined. Visual field was tested
by kinetic perimetry according to Goldmann12.
Main outcome measures
In the acute optic neuritis group, the clinical diagno-
sis of optic neuritis was based on the following criteria:
sensation of blurred vision, decreased visual acuity,
retrobulbar pain, relative afferent pupillary defect and
visual field defects. The eye involved by optic neuritis
was considered affected, and the contralateral one as
fellow eye. In the subjective symptom group, the eye in-
volved by subjective discomforts was considered affect-
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TABLE 1
DEMOGRAPHIC AND CLINICAL DATA






n 40 40 40
Age (years) 18–45 (mean 29.225±SD 6.9) 18–45 (mean 29.125±SD 8.1) 18–43 (mean 29.75±SD 8.3)
Female (%) 25 (62.5%) 28 (70%) 24 (60%)
Male (%) 15 (37.5%) 12 (30%) 16 (40%)
MS duration (years) 1–17 (mean 6.025±SD 3.8) 2–16 (mean 5.85±SD 4.5) 1–13 (mean 5.575±SD 3.8)
Symptoms duration (hours) 12–55 (mean 33.425±SD 13.3) 6–90 (mean 44.1±SD 24.5) 0
EDSS* 1–5 (mean 2.9625±SD 0.9) 1–3.5 (mean 2.45±SD 0.8) 1–3.5 (mean 2.25±SD 1.0)
* EDSS – An expanded disability status scale according to Kurtzke (11)
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ed, and the contralateral one as fellow eye. Subjective
discomforts were described as blurred vision on one eye,
occasionally accompanied by painful eye movements.
The eye exhibiting subjective symptoms is below re-
ferred to as affected eye, and the contralateral eye as fel-
low eye. In the subjective symptom-free group there
were no subjective signs of impaired vision and all sub-
jects had normal visual acuity, thus there was no differ-
entiation between affected and fellow eye.
Assessment of a visual field defect is based on the fol-
lowing criteria:
• grade 1, normal finding
• grade 2, mild narrowing of isopters by 10–15°
• grade 3, moderate narrowing of isopters by more than
15° with blind spot enlargement and occasional ab-
sence of inner isopters
• grade 4, moderate narrowing of isopters by more than
15° with blind spot enlargement, occasional absence
of inner isopters and presence of paracentral or arcu-
ate scotomata
• grade 5, narrowing with the presence of central or
cecocentral scotomata, blind spot enlargement and
absence of inner isopters
Ophthalmologic examination and visual field testing
were performed on two occasions at least 6 months
apart. In the acute optic neuritis group, initial examina-
tion and visual field testing were performed at the onset
of optic neuritis, whereas control examination and vi-
sual field testing were performed 6 months from ther-
apy completion. In the subjective symptom group, initial
examination and visual field testing were performed at
the time of the occurrence of subjective discomforts,
whereas control examination and visual field testing
were performed at the time free from subjective discom-
forts. In the subjective symptom-free group, ophthal-
mologic examination and visual field testing were per-
formed on two occasions at a 6-month interval.
Statistical analysis
Differences in the prevalence of particular grades of
visual field defects (grades 1–5) among the three patient
groups were determined by 2-test or Fisher exact test
for either eye in separate at initial and control examina-
tion. In case of statistically significant differences, Bon-
ferroni method of multiple comparison was used to iden-
tify the groups of patients with statistically significant
between-group differences13.
The difference between the affected and fellow eye in
groups 1 and 2 was tested by Friedman test for depend-
ent samples on initial and control examination. Fried-
man test was also used to assess differences between
the results of initial and control visual field testing for
the affected and fellow eye in separate14. P-values <0.05
were considered statisticaly significant. All statistical
analysis were done using the SAS 8.015.
Results
On initial testing, all patients had normal visual acu-
ity except for the affected eye in the acute optic neuritis
group patients. Nine of patients in the acute optic neuri-
tis group had visual acuity worse than 5/60, 26 patients
had visual acuity from 6/60 to 6/15, and five patients
from 6/12 to 6/10 according to Snellen chart. On control
testing, all patients had normal visual acuity. Compari-
son of the results obtained by visual field testing accord-
ing to study groups revealed grades 1 and 2 defects, i. e.
mild to moderate visual field narrowing with blind spot
enlargement, to be the most common form of impair-
ment, except for the acute optic neuritis group where
narrowing with central or cecocentral scotomata was
the most common form of visual field defect on the af-
fected eye, recorded in 60% of patients (Table 2). In the
subjective symptom group consisting of patients with
subjective signs of visual impairment but with normal
visual acuity on initial testing, the following results
were recorded for the affected and fellow eyes: mild vi-
sual field narrowing in 30% and 55%; moderate visual
field narrowing with blind spot enlargement in 47.5%
and 22.5%; and paracentral and arcuate scotomata in
15% and 10% of subjects, respectively (Table 2). In the
subjective symptom-free group, mild visual field nar-
rowing and moderate visual field narrowing with blind
spot enlargement were most common defects (Table 2).
In the acute optic neuritis group, recovery of the vi-
sual field on the affected eye (Friedman test=29.688,
p=0.001) and fellow eye (Friedman test=14.222, p=
0.001) was recorded, (Table 2) whereas visual field de-
fects were more pronounced on the affected eye at both
initial (2=62.424, p=0.001) and control (2=23.193, p=
0.001) testing (Table 2). On control testing, visual field
recovery on both the affected eye (Friedman test=
12.000, p=0.001) and fellow eye (Friedman test=8.00,
p=0.05) was also observed in the subjective symptom
group (Table 2). In this group, higher grade visual field
defects were recorded on initial testing on the affected
eye (Fisher exact test=7.571, p=0.058), whereas on con-
trol testing these defects were comparable between the
affected and fellow eyes (Fisher exact test=3.685, p=
0.305) (Table 2).
In Subjective symptom-free group there were no sig-
nificant visual field changes between the initial and
control testing (Table 2). Analysis of difference in the re-
sults of visual field control testing between the affected
and fellow eyes in the subjective symptom group and of
the two eyes in the subjective symptom-free group sho-
wed a comparable distribution of defect severity in the
two groups (2=6.3, p=0.39) (Table 3). Analysis of differ-
ence in the results of visual field control testing between
the affected and fellow eyes in the acute optic neuritis
group and of the two eyes in the subjective symp-
tom-free group pointed to a higher proportion of the
moderate form of visual field defect with blind spot en-
largement and moderate defect with paracentral and
arcuate scotoma on both eyes in the subjective symp-
tom-free group (2=29.36, p=0.01). Multiple post hoc
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mutual testing showed a higher proportion of the de-
fects described above on the affected eye in the acute op-
tic neuritis group (p=0.03) and on both eyes in the sub-
jective symptom-free group (p<0.001). Also, there was
similar distribution of the visual field defects on the af-
fected eye in the acute optic neuritis group and on both
eyes in the subjective symptom-free group (p=0.378)
(Table 3).
Discussion
Although optic neuritis is considered to be the most
common form of visual function impairment in multiple
sclerosis patients5, this study revealed that visual field
defect may also be present in those multiple sclerosis
patients who have never had optic neuritis. In our sub-
jective symptom-free group, 57.5% of patients had vi-
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TABLE 2
RESULT OF VISUAL FIELD TESTING IN ALL GROUPS
No. (%) of eyes in the group
Visual field
changes
Optic neuritis group Subjective symptoms group
Subjective symp-
toms-free group































Normal finding 0 13 (32.5) 16 (40) 27 (67.5) 2 (5) 8 (20) 5 (12.5) 11 (27.5) 24 (30) 24 (30)
Mild narrowing 0 4 (10) 16 (40) 10 (25) 13 (32.5) 11 (27.5) 22 (55) 16 (40) 22 (27.5) 22 (27.5)
Moderate narrowing with
blind spot enlargement
and occasional absence of
inner isopters
5 (12.5) 14 (35) 6 (15) 1 (2.5) 19 (47.5) 18 (45) 9 (22.5) 10 (25) 24 (30) 24 (30)
Narrowing with the
presence of arcuate or
paracentral scotoma with
blind spot enlargement
10 (25) 9 (22.5) 2 (5) 2 (5) 6 (15) 3 (7.5) 4 (10) 3 (7.5) 10 (12.5) 10 (12.5)
Narrowing with the
presence of central or
cecocentral scotomata
25 (62.5) 0 0 0 0 0 0 0 0 0
TABLE 3
COMPARISON OF RESULTS OF CONTROL VISUAL FIELD TESTING IN ACUTE OPTIC NEURITIS GROUP AFFECTED AND
FELLOW EYES, OF SUBJECTIVE SYMPTOM GROUP AFFECTED AND FELLOW EYE, AND OF CONTROL VISUAL FIELD TESTING
IN SUBJECTIVE SYMPTOM-FREE GROUP






















testing (n = 80)
Normal finding 13 (32.50) 27 (67.50) 8 (20.00) 11 (27.50) 24 (30.00)
Mild narrowing 4 (10.00) 10 (25.00) 11 (27.50) 16 (40.00) 22 (27.50)
Moderate narrowing
with blind spot enlarge-
ment and occasional ab-
sence of inner isopters
14 (35.00) 1 (2.50) 18 (45.00) 10 (25.00) 24 (30.00)
Narrowing and presence
of arcuate or paracentral
scotoma with blind spot
enlargement
9 (22.50) 2 (5.00) 3 (7.50) 3 (7.50) 10 (12.50)
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sual field defect although they had no history of optic
neuritis or any subjective signs of impaired vision. A
similar finding has also been recorded by Patterson and
Heron16, who report on the majority of their study sub-
jects to have visual field defect without a history of optic
neuritis. However, Burde and Gallin17 found their study
subjects to have normal field of vision. This discrepancy
could be attributed to different techniques of visual field
testing used in the two studies. In the latter, visual field
was tested by use of I2–I4 isopters, whereas we used
and a I1 isopter (lower relative intensity test spot). The
behavior of I1 isopter is of special importance, as it is lo-
cated in the intermediary zone which is sensitive to var-
ious pathologic conditions12.
In the subjective symptom-free group, mild to moder-
ate narrowing and blind spot enlargement were the
most common defects. Such asymptomatic visual field
defects (negative scotomata) could be explained by their
localization in the eccentric, peripheral visual field seg-
ments, bilateral occurrence and slow progression, thus
being quite inapparent. Such a picture is opposite to
that of acute optic neuritis, which is considered the most
common visual lesion in patients with multiple sclero-
sis, where it is the reason for their visit to an ophthal-
mologist.
In the present study, visual field defects were catego-
rized according to the prevalence of particular forms of
these defects. On control testing, mild to moderate nar-
rowing with blind spot enlargement was the most com-
mon form of visual field defects. The visual field defects
found in our patients were comparable to those reported
elsewhere18–20. Although a higher prevalence of arcuate
scotomata is being reported elsewhere16,18,21, the varia-
tion could be attributed to different methods of visual
field testing, since some authors used automated pe-
rimetry and others employed Bjeruum's screen. As pa-
tient selection is also important, it should be noted that
only patients with normal visual acuity were included
in our study. Nevertheless, the results appear to be
quite similar. Narrowing and occasionally absence of in-
ner isopters accompanied by blind spot enlargement
were recorded in the majority of our patients. Inner
isopters reflect changes in the very 10
–15
 area, in
which other authors found defects18. Some of our results
are quite comparable with those reported by Nizankow-
ska et al21, because depression from above was also re-
corded in some of our patients, however, in contrast to
our study, these authors found no blind spot enlarge-
ment. This variation could also be ascribed to the use of
a different method of visual field testing, i.e. automated
perimetry19,21. They performed visual field testing wi-
thin 30°, which is highly relevant in the light of our de-
tecting defects in peripheral areas of the visual field, not
only in central areas within 30°. Comparison of the re-
sults of control visual field testing performed during the
quiescent stage showed visual field narrowing and blind
spot enlargement to be the most common defects in all
study groups. The higher proportion of normal visual
field in the acute optic neuritis group could be ascribed
to the administration of pulsed therapy, which was not
used in the other two groups. Visual function impair-
ment in the acute phase is explained by inflammation
and oedema that lead to conductivity interruption. The
possible visual function recovery occurs due to restored
conductivity following regression of oedematous and in-
flammatory lesions, and partially due to early remy-
elination. Such recovery usually occurs within 3–6
months22. Late recovery of visual function could be at-
tributed to longterm remyelination. Demyeliantion, which
may be followed by axonal degeneration, is known to be
involved in plaque evolution23,24. An active process of
demyelination is accompanied by myelin and oligoden-
drocyte destruction within the plaque. Oligodendrocytes
were found to be significantly reduced in MS patients
who died within one month of the clinical manifestation
of the disease. Also, demyelination may be followed by
remyelination, which can halt the degeneration of de-
myelinating axons, i.e. axonal destruction25. Prineas et
al25 found the rate of plaques with signs of remyeli-
nation (shadow plaques) to markedly increase only 12
weeks of the initial clinical manifestation of the disease.
However, these shadow plaques may be exposed to
demyeliantion and be converted to classic demyelina-
ting plaques26. Jones et al explain the recovery of VEP
parameters by the process of remyelination, redistribu-
tion of ion channels, and potential cortical restructur-
ing, emphasizing that this pattern of recovery can only
be observed in 2–3 years22.
The presence of fellow eye lesion in the acute optic
neuritis group on initial testing (during the course of
acute optic neuritis) could be explained by dissemina-
tion of the inflammation from the affected eye23,24.
Other authors also report on visual field impairment on
the fellow eye27,28. As visual field recovery was also re-
corded on the fellow eye, these impairments were not
likely to be caused by longstanding lesions23,24. Beck et
al27 also describe recovery of the visual field on the fel-
low eye with steroid therapy.
It cannot be stated for sure whether the inapparent
visual field impairments were caused by optic nerve
demyelination or involvement of other segments of the
visual pathway5. Optic tract involvement is frequently
found on autopsy and magnetic resonance neuroradio-
logy in multiple sclerosis patients. The tight fiber struc-
ture of the optic nerve sheath is highly sensitive to
pathologic lesions. Although posterior segments of the
vision pathway are also frequently involved, there is
great disparity between the pathologic lesions and clini-
cal signs, which could be explained by anatomic disper-
sion of the visual fiber in the sphere of vision. A minor
plaque in this posterior segment of the vision pathway
may involve a smaller number of fibers than in the optic
nerve itself. This would result in a relatively rare mani-
festation of such characteristic visual field lesions. Also,
such plaques may be asymptomatic as they cause chan-
ges in the peripheral segment of the visual field. Minor
scotomata cause only mild changes in the field of vision
without affection of the central visual acuity. Subjec-
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tively inapparent visual field defects may also be caused
by subtle degenerative processes, oligodendropathy, and
loss of axons5,29–31. Multiple sclerosis is not only associ-
ated with demyelination but also with axonal damage
and degeneration as well as with anatomic and bio-
chemical changes of axons within the MS lesion2. Brusa
et al24 think that visual function impairment occurs con-
sequentially to irreversible axonal degeneration rather
than demyelination. They believe that the failure of vi-
sual field recovery in their study was due to irreversible
axonal degeneration. Accordingly, the presence of visual
field impairment in our subjective symptom-free group
could have also been due to the presence of irreversible
axonal degeneration. In this group there were no signifi-
cant visual field changes between the initial and control
testing.
Results of the study showed the standard ophthal-
mologic examination with manual visual field testing to
record mild defects in patients free from subjective
symptoms but to provide inadequate data on the visual
system lesion. This points to the need of comparative
ophthalmologic functional diagnosis in patients with
multiple sclerosis, and especially in those free from
acute optic neuritis episodes. Further studies are need-
ed to evaluate the introduction of contrast sensitivity
testing, visual field testing with automated perimetry
and visual evoked potential testing to provide addi-
tional information on the vision system involvement in
multiple sclerosis patients.
In conclusion, the study showed the visual field de-
fects to be also present in MS patients free from a his-
tory of optic neuritis. In contrast to other literature re-
ports, three patient groups were compared. In addition
to the groups of MS patients with optic neuritis and
those without a history of optic neuritis, that have been
most largely investigated to date, we differentiated a
third group of patients with subjective signs of vision
impairment and normal visual acuity. A similar group
has also been described by Frederiksen et al32 however,
without comparing them with other patient groups.
Furthermore, all our patients had normal visual acuity
on control testing. Our study has entailed highly rele-
vant findings of a similar distribution of visual field de-
fects across all study groups in the quiescent stage of
the disease, when there were no signs of vision function
impairment, and of the high prevalence of peripheral vi-
sual field defects. As the study showed the visual field
defects to be located in the peripheral areas of the field
of vision and to progress slowly, they proceed unnoticed
by MS patients. This points to the role of perimetry in
the early recognition of MS patients while still free from
subjective disturbances. As visual field testing has to
date been mostly focused on the central part of the field
of vision, this study emphasizes the need of including
peripheral areas in visual field testing.
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NEZAMIJE]ENA O[TE]ENJA VIDNOG POLJA U BOLESNIKA KOJI BOLUJU
OD MULTIPLE SKLEROZE
S A @ E T A K
Utvrditi nezamje}ena o{te}enja vidnog polja u bolesnika s multiplom sklerozom koji nisu imali opti~ki neuritis.
Tijekom 5 godina pregledano je 120 bolesnika koji boluju od multiple skleroze na Klinici za o~ne bolesti Medicinskog
fakulteta KBC Rebro zagreb. Oni su podijeljeni u tri skupine sa po 40 ispitanika svaka: ispitanici koji su se javili
oftalmologu zbog akutnog opti~kog neuritisa i lije~eni pulsnom steroidnom terapijom, ispitanici sa subjektivnim zna-
cima zamu}enja vida, urednom vidnom o{trinom i bez znakova opti~kog neuritisa, te ispitanici bez subjektivnih zna-
kova o{te}enja vida. U istra`ivanju je u~injen standardni oftalmolo{ki pregled, te testiranje vidnih polja Goldmann
kineti~kim perimetrom. Inicijalno i kontrolno testiranje u~injeno je u razmaku od 6 mjeseci. Istra`ivanje je pokazalo
da 65% bolesnika s multiplom sklerozom bez subjektivnih znakova ima o{te}enje vidnog polja. Naj~e{}i oblici o{te-
}enja su bla`e do umjereno su`eno sa pro{irenjem slijepe pjege uz depresiju odozgo. Utvr|eni su slijede}i rezultati:
acute optic neuritis group: uredan nalaz u 13/40 (32.5%) za zahva}eno oko, te 27/40 (67.5%) za prate}e oko; bla`e
su`enje vidnog polja u 4/40 (10%) za zahva}eno, te 10/40 (25%) za prate}e oko; umjereno su`enje uz pro{irenje slijepe
pjege u 14/40 (35%) za zahva}eno oko, te 1/40 (2.5%) za prate}e oko; paracentralni i arkuatni skotomi u 9/40 (22.5%)
za zahva}eno oko, te 2/40 (5%) za prate}e; subjective symptom group: uredan nalaz u 8/40 (20%) za zahva}eno oko, te
11/40 (27.5%) za prate}e oko; bla`e su`enje vidnog polja u 11/40 (27.5%) za zahva}eno oko te 16/40 (40%) za prate}e
oko; umjereno su`enje uz pro{irenje slijepe pjege u 18/40 (45%) za zahva}eno te 10/40 (25%) za prate}e oko; i para-
centralni i arkuatni skotom u 3/40 (7.5%) za oba oka; i subjective symptom-free group: uredan u 24/80 (30%), bla`e
su`enje u 22/80 (27.5%) umjereno su`enje s pro{irenjem slijepe pjege u 24/80 (30%); te prisutnost paracentralnih i
arkuatnih skotoma u 10/80 (12.5%) ispitanika. Prisutnost supklini~kog oblika zahva}anja vidnog `ivca mo`e se utvr-
diti u vrlo ranoj fazi multiple skleroze uvo|enjem testiranja vidnog polja u standardni protokol.
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